Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

RGT-61159

RGT-61159 Phase 3 (planned, not yet registered)

Rgenta Therapeutics · Phase 3 · Not yet recruiting · Enrollment 150

Registry id n/r

Catalyst Phase 3 start (company plan). Q1 2027. Company release 10.22.2026: start planned 1Q 2027.

ArmReported safety
RGT-61159 84 mg + best supportive caren/r
RGT-61159 60 mg + best supportive caren/r
Placebo + best supportive caren/r

A count stays a count. This page does not turn a count into a percent.